Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-infiltrating immune cells (TIICs) are a diverse population of immune cells found within the tumor microenvironment. These cells, including macrophages, neutrophils, NK cells, DCs, MDSCs, Tregs, T lymphocytes, and B lymphocytes, play complex and often opposing roles in cancer progression. They can exert anti-tumor effects through direct cytotoxicity and promotion of adaptive immunity, but also pro-tumor effects by suppressing immune responses, promoting angiogenesis, and creating an immunosuppressive environment. The balance between these opposing activities determines the overall impact of TIICs on tumor growth and metastasis. Their presence and functional state are critical determinants of prognosis and therapeutic response.
Varies depending on the specific immune cell type and therapeutic agent. Includes blocking immune checkpoints, depleting immunosuppressive cells, and reprogramming immune cell phenotypes.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor-Infiltrating Immune Cells (TIICs).